Viking Therapeutics Inc Stock

Viking Therapeutics (NASDAQ: VKTX) has seen its stock stumble in recent times -- for example, it's slipped over the past year. But over five years, shares of the biotech company have climbed more

An analyst at the banking giant Truist Financial has an $83 price target on Viking Therapeutics (NASDAQ: VKTX), which is particularly notable given that Viking opened at $28.75 per share on June 8

Despite being one of the NFL's most winningest franchises, the Minnesota Vikings have never won a Super Bowl. Viking Holdings (NYSE: VIK), on the other hand, is winning it all in its market. Shares

The debate over Viking Therapeutics (NASDAQ: VKTX) will take another turn in Q3. As ever, you have to factor in what competitors such as Eli Lilly and Novo Nordisk are doing, as well as the unique

The key to understanding the investment case for Viking Therapeutics (NASDAQ: VKTX) stock lies in the benefits of having a weight-loss drug, namely VK2735, in development in both subcutaneous

It doesn't seem right. All three major cruise line stocks have been lagging the market over the past year, with gains of 4% to 21%. Then you have Viking Holdings (NYSE: VIK), which has soared 108%

From late 2023 to early 2024, Viking Therapeutics (NASDAQ: VKTX) took off like a rocket, as it seemed that the clinical-stage biotech company would become the dark-horse candidate among GLP-1 stocks

Viking Therapeutics (NASDAQ: VKTX) increasingly looks like an acquisition candidate in biotech. But why?

It's because large pharmaceutical companies are desperate to secure obesity drug exposure

The famously volatile biotech industry can help investors earn substantial returns in relatively short periods, so long as they pick the right companies. Take Abivax (NASDAQ: ABVX) and Viking

Eli Lilly (NYSE: LLY) wasn't the first to conquer the weight loss drug market. Novo Nordisk started the ball rolling back in 2017, when it won approval for its GLP-1 drug, Ozempic. Though Ozempic

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) dominate the weight-loss drug market and have for a while. What's more, recent launches are helping them expand this area and attract new patients.

Most stocks would take a hit after a company announces the exit of its founder-CEO on the same morning it posts financial results that fell roughly in line with expectations. Viking Holdings (NYSE:

There's a lot on the minds of Viking Holdings (NYSE: VIK) shareholders heading into this week's financial update. Unlike the more traditional cruise line operators that have already reported this

Investors are turning away from somewhat speculative and unprofitable stocks right now, given the significant volatility and economic-related uncertainty we face. But what if this rotation is

It's not unheard of for biopharma stocks to deliver big gains in relatively short periods; the development of a game-changing drug is usually the catalyst. Even by biopharma standards, though, what

Billionaire investor Warren Buffett has said in the past that "the stock market is a device for transferring money from the impatient to the patient."

While it's easy to get caught up in chasing

Pharmaceutical and biotech companies may offer your portfolio a sense of stability, and this is for one good reason: Patients need their medical treatments, so they will continue going for them

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech company, went public almost 11 years ago. Since then, the drugmaker's stock has performed well, while it has made significant clinical